NASDAQ:ALZN
Alzamend Neuro, Inc.
Alzamend Neuro, Inc. reported net income of −$8.8M in fiscal 2026. The diluted share count rose 640.3%.Summary generated from Alzamend Neuro, Inc.'s SEC filings. Latest annual report filed Jul 22, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−373.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+640.3%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −12 | −15 | −10 | −4 | −9 |
| Net income | −12 | −15 | −10 | −5 | −9 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Sep 29, 2026 - 10-QQuarterly report for the period ended Jul 31, 2026
Sep 10, 2026 - 4Insider transaction report
Aug 31, 2026 - S-1Registration statement
Aug 21, 2026 - 4Insider transaction report
Aug 4, 2026 - 8-KEntry into a material agreement
Aug 3, 2026 - 10-KAnnual report for the fiscal year ended Apr 30, 2026
Jul 22, 2026 - 8-KOther events
Jul 21, 2026